Drug for common inflammatory bowel disease may blunt COVID-19 vaccine response - Study - Android

New Delhi, Apr 27: People who take a commonly-prescribed medicine for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, according to a study that found many such people had poor antibody response.